GlaxoSmithKline will partner with Germany’s CureVac to manufacture 100 million doses of that company’s mRNA COVID-19 vaccine, CVnCoV, and will collaborate with the company to develop a next-generation multi-valent COVID-19 vaccine aimed at emerging variants of the novel coronavirus.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
In July, the two companies partnered to develop up to five messenger RNA (mRNA)-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The terms of that deal included GSK acquiring a 10% stake in the German company.
The latest collaboration between the two companies noted that GSK and CureVac will contribute resources and expertise to research, develop and manufacture a number of novel mRNA vaccine candidates, including multi-valent and monovalent approaches.
This collaboration will build on CureVac’s first generation COVID-19 vaccine candidate CVnCoV, which is currently in Phase IIb/III clinical trial and on CureVac’s ability to optimize mRNA for a strong immune response.
Under the terms of the new collaboration agreement, GSK will be the marketing authorization holder for the next-generation vaccine, except in Switzerland, and will have exclusive rights to develop, manufacture, and commercialize the next generation COVID-19 vaccine in all countries with the exception of Germany, Austria and Switzerland.
Last month, CureVac partnered with Bayer on the development of its first-generation mRNA vaccine. Under the terms of the agreement, Bayer will support the development, supply and key territory operations of CVnCoV. Bayer will contribute its “expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries,” the companies said.